Potentially, yes. Aetna's current commercial medical policy states that Spravato can be medically necessary for specified FDA-approved depressive indications when its criteria are met. Precertification is required for applicable plan designs.
Aetna's policy is not a guarantee that a particular member will be covered. The member's actual plan benefits, clinical circumstances, network status, authorization, and cost-sharing still control what the patient pays.
If a user selects Aetna and indicates that insurance is important, the matching system increases the rank of Spravato providers for which we have public evidence of Aetna participation. We still tell the user to verify exact benefits directly.
Aetna Clinical Policy Bulletin 0950, last reviewed February 25, 2026. Read the Aetna policy
Answer 13 questions about insurance, budget, location, treatment preference, and care preferences. Ketamine Compass will rank relevant options from our provider dataset.
Show my matches